Amgen

Amgen

AmgenAmgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. For more information, please visit http://www.amgen.com

Amgen RSS Channel

Filters
List of articles in category Amgen
Title Published Date
Amgen and the Amgen Foundation commit up to $12.5 million to support COVID-19 relief efforts 27 March 2020
Amgen commences strategic collaboration with BeiGene to expand oncology presence in China 06 January 2020
Amgen to acquire Otezla® for $13.4 billion in cash 27 August 2019
Amgen and Allergan announce positive top-line results from comparative clinical study of ABP 798, biosimilar candidate to Rituxan® (rituximab) 23 August 2019
Amgen joins with community oncology networks for new research collaboration 29 May 2019
Amgen ignites a social fitness movement to support the fight against heart disease and cancer 03 May 2019
Amgen invests £50 million ($66 Million) in Oxford Nanopore Technologies 19 October 2018
Amgen launches AMGEVITATM (biosimilar adalimumab) in markets across Europe 17 October 2018
World's largest Alzheimer's survey reveals most adults believe a cure will be developed in their lifetime 19 September 2018
Amgen and Novartis present new data demonstrating long-term efficacy, safety and tolerability of Aimovig TM (erenumab-aooe) in patients with chronic and episodic migraine 28 June 2018
Amgen to begin launching biosimilar adalimumab in Europe in 2018 28 September 2017
Amgen to acquire Mustafa Nevzat, a leading privately held Turkish pharmaceutical company 25 April 2012
XGEVA® (Denosumab) Granted Marketing Authorization in the European Union 06 September 2011
Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination with Chemotherapy 27 June 2011
Amgen's First Quarter 2011 Revenue Increased 3 Percent to $3.7 Billion 21 April 2011
Amgen Statement on CHMP Opinion on Vectibix(R) (Panitumumab) 17 March 2011
Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 06 October 2010
Amgen Announces Top-Line Results of Phase 3 Head and Neck Cancer Trial 18 August 2010
Prolia(R) (Denosumab) Granted Marketing Authorization in the European Union 31 May 2010
Amgen Receives CHMP Positive Opinion for Prolia(TM) (Denosumab) in the European Union 21 December 2009